Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.
about
Nitric oxide and pH modulation in gynaecological cancerThe PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challengesA novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgraftsExpression and clinical significance of the autophagy proteins BECLIN 1 and LC3 in ovarian cancerATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancersCisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian TumorsFOXO1/3 and PTEN Depletion in Granulosa Cells Promotes Ovarian Granulosa Cell Tumor Development.Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancerResistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicityPreoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC ConsortiumRepeated ovarian stimulation does not affect the expression level of proteins involved in cell cycle control in mouse ovaries and fallopian tubes.Heat shock protein 70-2 (HSP70-2) a novel cancer testis antigen that promotes growth of ovarian cancer.The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.Oxysterols synergize with statins by inhibiting SREBP-2 in ovarian cancer cellsInvestigational agents in development for the treatment of ovarian cancerMirk kinase inhibition targets ovarian cancer ascites.Decitabine reactivated pathways in platinum resistant ovarian cancer.Overview of a chemoresponse assay in ovarian cancerAntiprogestins in gynecological diseases.Characterization of ascites-derived ovarian tumor cells from spontaneously occurring ovarian tumors of the chicken: evidence for E-cadherin upregulation.p70 S6 kinase drives ovarian cancer metastasis through multicellular spheroid-peritoneum interaction and P-cadherin/b1 integrin signaling activation.Endometriosis and ovarian cancer.Polymorphisms in the vitamin D Receptor (VDR) and the risk of ovarian cancer: a meta-analysis.An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinomaA quantitative proteomics-based signature of platinum sensitivity in ovarian cancer cell lines.Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancerNF-κB inducing kinase, a central signaling component of the non-canonical pathway of NF-κB, contributes to ovarian cancer progression.Eradication of Human Ovarian Cancer Cells by Transgenic Expression of Recombinant DNASE1, DNASE1L3, DNASE2, and DFFB Controlled by EGFR Promoter: Novel Strategy for Targeted Therapy of Cancer.Fibroblast growth factor 9 activates akt and MAPK pathways to stimulate steroidogenesis in mouse leydig cellsRecurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma.The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and BakOncolytic virotherapy for ovarian cancer.Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells.Minireview: animal models and mechanisms of ovarian cancer development.High expression of S100P is associated with unfavorable prognosis and tumor progression in patients with epithelial ovarian cancerDNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.Advantages of the avian model for human ovarian cancerAmplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival
P2860
Q26741063-9BC9EC9D-6244-41CD-9A01-7EA428070420Q26851852-04131434-D26E-43CA-ACEC-4BC31176338EQ27346392-46A4376E-B4CD-4E15-AD31-05D3423DE270Q28246311-E34FAD91-A33C-4222-91B2-0E4A1F111156Q28271111-68B6C978-18ED-49E4-8909-1B11723DC5F3Q28550863-387A6B9F-30BB-4148-9DAA-3C5A82FB71CDQ30358011-87985E35-AECC-408F-B82C-3AAFB50F9281Q30409503-1EEBBF28-7A50-414E-A40B-783C78FE0AB8Q33554192-CF18B788-A176-47C1-8F7A-7AA105BCFD9EQ33624809-8517E12D-2522-4355-9347-E26A351F1A06Q33722020-6E160BBD-FCA3-42F0-B73D-469A6590F0DBQ33850034-C4F44B08-398F-4BE8-A9C5-3D6BAF1C95CBQ33911286-E27F6F4D-90E8-472E-B692-D71C02348D52Q33917134-CEA82BCA-01B2-490F-AADF-4A734C6DF9E4Q33920800-DA4D2F49-B58C-45A9-A6FC-5082895FA3A5Q33925352-B3A57E47-8107-4B71-89B9-C0FDD27B06A9Q33976957-5D737CDB-4780-4ACF-A5BC-D8DA5C871FA1Q34071625-13BB9A4A-FF22-4D98-973E-EF0D99BAEBBAQ34587636-BDFDE9D8-F391-407F-A333-19374B84745CQ34608699-0B36719A-C5F7-4850-977D-5FB1FE2C5B33Q34619266-1AAB9E50-13CF-4355-B52C-5692780179A8Q34657664-8B2CF408-5231-4A0B-A40E-BE8F4C20A222Q34795858-1BDC118C-2FA0-4964-BFC4-D94608978F1CQ34926232-74F3BDAA-B78B-4963-8C25-B7F57AC0409DQ35031170-31F31591-4689-4409-9AF8-38E9DC2F8244Q35064627-5575AC94-C1D7-4097-932F-95803E891AE3Q35095325-FC723FCC-5FB8-4FAE-BE14-723CAA16626BQ35109273-3E1245D5-9E02-4BD2-BA4F-E1496C97D462Q35113258-C9C51284-5FD4-468C-B20C-A08935188483Q35212656-C8A354AB-35D5-4A51-8B73-EDCACA9894C4Q35541834-9B065C0D-E306-4176-A259-7A9F3CB05C0EQ35597082-0D3B1100-B286-486B-849C-25A4C82445FFQ35767493-A90167BC-6409-483D-9680-4D08F4A0A40EQ35872732-F052B631-8074-4661-AB92-EDF95E45F091Q36057106-B5BEB898-48B4-4D2B-BDB0-03C410E24BCAQ36213219-763130FB-490C-4699-B470-12A30F2ACE2DQ36245791-EB66CC3A-F4B7-45BF-9BD6-7C911D60FC6AQ36309603-F6B99CE8-037C-413C-B2C3-2EB68C665104Q36334681-7C280157-1B7F-46AF-A71F-4F00CDC95E3FQ36341198-1BC8BC02-FBE1-49B7-825B-7A3E40C29185
P2860
Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Minireview: human ovarian canc ...... aths to personalizing therapy.
@ast
Minireview: human ovarian canc ...... aths to personalizing therapy.
@en
type
label
Minireview: human ovarian canc ...... aths to personalizing therapy.
@ast
Minireview: human ovarian canc ...... aths to personalizing therapy.
@en
prefLabel
Minireview: human ovarian canc ...... aths to personalizing therapy.
@ast
Minireview: human ovarian canc ...... aths to personalizing therapy.
@en
P2860
P356
P1433
P1476
Minireview: human ovarian canc ...... aths to personalizing therapy.
@en
P2093
Ignacio Romero
P2860
P304
P356
10.1210/EN.2011-2123
P407
P577
2012-03-13T00:00:00Z